<DOC>
	<DOCNO>NCT00171119</DOCNO>
	<brief_summary>The purpose study evaluate efficacy valsartan , benazepril combination reduction microalbuminuria Type 2 diabetic patient .</brief_summary>
	<brief_title>A Study Patients With Diabetes Mellitus Type II Effect Albuminuria 24 Week Treatment With Valsartan , Benazepril , Valsartan+Benazepril</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Benazepril</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>male female patient age 3575 year type 2 diabetes mellitus recent evidence persistent microalbuminuria patient median ( 3 sample ) time overnight UAER microalbuminuric range 20200 g/min formal screening period prior entry patient give write , sign , informed consent . patient with/without mild /moderate hypertension . patient hypertensive treatment , already treatment , accept enter 3 week notreatment washout period switch treatment . patient without accompany systemic disease pregnant nursing woman , woman childbearing potential use acceptable method contraception patient type I diabetes mellitus define onset age 35 year require insulin within first year diagnosis Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>HYPERTENSION</keyword>
	<keyword>DIABETES MELLITUS TYPE II</keyword>
	<keyword>VALSARTAN</keyword>
	<keyword>BENAZAPRIL</keyword>
</DOC>